Eli Lilly (LLY) 财报连锁
5 个阶段 · 3 个历史事件
连锁传导流
Eli Lilly's Mounjaro/Zepbound sales and clinical trial readouts set expectations for the entire GLP-1 obesity market.
Novo Nordisk and Lilly form a GLP-1 duopoly; positive class data lifts both, while competitive data creates relative winners and losers.
Pfizer's oral GLP-1 candidate (danuglipron) is a distant follower; strong Lilly data validates the obesity market while highlighting Pfizer's competitive gap.
Moderna benefits from broader biopharma innovation sentiment but has no direct GLP-1 program; moves are sentiment-driven.
Regeneron's antibody platform may produce GLP-1 alternatives; the company reacts to obesity-market sizing and competitive dynamics.
历史案例
触发条件
Eli Lilly Q1 2024: Mounjaro revenue $1.8B (+219% YoY), Zepbound launched at $500M+ run-rate in first quarter
龙头异动:
LLY +6.3%连锁结果
NVO +3% (class validation), PFE -1.5% (competitive pressure on oral GLP-1 timeline). Broader biotech ETF (XBI) +2%.
触发条件
Eli Lilly Phase 3 orforglipron (oral GLP-1) data showed 14.7% weight loss — better than expected
龙头异动:
LLY +4.5%连锁结果
NVO -3.2% (oral GLP-1 competitive threat). PFE -2% (danuglipron outlook further dimmed). REGN +1% on obesity market expansion thesis.
触发条件
Eli Lilly retatrutide (triple agonist) Phase 3 results: 26% body weight loss at 48 weeks — best in class
龙头异动:
LLY +8.1%连锁结果
NVO -5% (competitive pressure), PFE -2%, REGN +2% (exploring anti-obesity antibodies). Bariatric surgery stocks fell 10-15%.
当前状态
未检测到活跃的连锁反应。下一个潜在触发因素是 LLY 财报发布。请关注业绩指引变化或预告信号。